Jianhua Wu1,2, Mamas Mamas3, Muhammad Rashid3, Clive Weston4, Julian Hains5, Tom Luescher6, Mark A de Belder5, John E Deanfield5,7, Chris P Gale1,8,9. 1. Leeds Institute for Data Analytics, University of Leeds, Worsley Building, Level 11, Clarendon Way, University of Leeds, Leeds LS2 9JT, UK. 2. Division of Clinical and Translational Research, School of Dentistry, University of Leeds, Leeds, UK. 3. Keele Cardiovascular Research Group, Institute for Prognosis Research, University of Keele, Keele, UK. 4. Glangwili General Hospital, Carmarthen, Wales, UK. 5. National Institute for Cardiovascular Outcomes Research, Barts Health NHS Trust, London, UK. 6. Imperial College, National Heart and Lung Institute, London, UK. 7. Institute of Cardiovascular Sciences, University College, London, UK. 8. Leeds Teaching Hospitals NHS Trust, Leeds, UK. 9. Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
Abstract
AIMS: COVID-19 might have affected the care and outcomes of hospitalized acute myocardial infarction (AMI). We aimed to determine whether the COVID-19 pandemic changed patient response, hospital treatment, and mortality from AMI. METHODS AND RESULTS: Admission was classified as non-ST-elevation myocardial infarction (NSTEMI) or STEMI at 99 hospitals in England through live feeding from the Myocardial Ischaemia National Audit Project between 1 January 2019 and 22 May 2020. Time series plots were estimated using a 7-day simple moving average, adjusted for seasonality. From 23 March 2020 (UK lockdown), median daily hospitalizations decreased more for NSTEMI [69 to 35; incidence risk ratios (IRR) 0.51, 95% confidence interval (CI) 0.47-0.54] than STEMI (35 to 25; IRR 0.74, 95% CI 0.69-0.80) to a nadir on 19 April 2020. During lockdown, patients were younger (mean age 68.7 vs. 66.9 years), less frequently diabetic (24.6% vs. 28.1%), or had cerebrovascular disease (7.0% vs. 8.6%). ST-elevation myocardial infarction more frequently received primary percutaneous coronary intervention (81.8% vs. 78.8%), thrombolysis was negligible (0.5% vs. 0.3%), median admission-to-coronary angiography duration for NSTEMI decreased (26.2 vs. 64.0 h), median duration of hospitalization decreased (4 to 2 days), secondary prevention pharmacotherapy prescription remained unchanged (each > 94.7%). Mortality at 30 days increased for NSTEMI [from 5.4% to 7.5%; odds ratio (OR) 1.41, 95% CI 1.08-1.80], but decreased for STEMI (from 10.2% to 7.7%; OR 0.73, 95% CI 0.54-0.97). CONCLUSION: During COVID-19, there was a substantial decline in admissions with AMI. Those who presented to hospital were younger, less comorbid and, for NSTEMI, had higher 30-day mortality. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: COVID-19 might have affected the care and outcomes of hospitalized acute myocardial infarction (AMI). We aimed to determine whether the COVID-19 pandemic changed patient response, hospital treatment, and mortality from AMI. METHODS AND RESULTS: Admission was classified as non-ST-elevation myocardial infarction (NSTEMI) or STEMI at 99 hospitals in England through live feeding from the Myocardial Ischaemia National Audit Project between 1 January 2019 and 22 May 2020. Time series plots were estimated using a 7-day simple moving average, adjusted for seasonality. From 23 March 2020 (UK lockdown), median daily hospitalizations decreased more for NSTEMI [69 to 35; incidence risk ratios (IRR) 0.51, 95% confidence interval (CI) 0.47-0.54] than STEMI (35 to 25; IRR 0.74, 95% CI 0.69-0.80) to a nadir on 19 April 2020. During lockdown, patients were younger (mean age 68.7 vs. 66.9 years), less frequently diabetic (24.6% vs. 28.1%), or had cerebrovascular disease (7.0% vs. 8.6%). ST-elevation myocardial infarction more frequently received primary percutaneous coronary intervention (81.8% vs. 78.8%), thrombolysis was negligible (0.5% vs. 0.3%), median admission-to-coronary angiography duration for NSTEMI decreased (26.2 vs. 64.0 h), median duration of hospitalization decreased (4 to 2 days), secondary prevention pharmacotherapy prescription remained unchanged (each > 94.7%). Mortality at 30 days increased for NSTEMI [from 5.4% to 7.5%; odds ratio (OR) 1.41, 95% CI 1.08-1.80], but decreased for STEMI (from 10.2% to 7.7%; OR 0.73, 95% CI 0.54-0.97). CONCLUSION: During COVID-19, there was a substantial decline in admissions with AMI. Those who presented to hospital were younger, less comorbid and, for NSTEMI, had higher 30-day mortality. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Thomas A Kite; Peter F Ludman; Chris P Gale; Jianhua Wu; Adriano Caixeta; Jacques Mansourati; Manel Sabate; Pilar Jimenez-Quevedo; Luciano Candilio; Parham Sadeghipour; Angel M Iniesta; Stephen P Hoole; Nick Palmer; Albert Ariza-Solé; Alim Namitokov; Hector H Escutia-Cuevas; Flavien Vincent; Otilia Tica; Mzee Ngunga; Imad Meray; Andrew Morrow; Md Minhaj Arefin; Steven Lindsay; Ghada Kazamel; Vinoda Sharma; Aly Saad; Gianfranco Sinagra; Federico Ariel Sanchez; Marek Roik; Stefano Savonitto; Marija Vavlukis; Shankar Sangaraju; Iqbal S Malik; Sharon Kean; Nick Curzen; Colin Berry; Gregg W Stone; Bernard J Gersh; Anthony H Gershlick Journal: J Am Coll Cardiol Date: 2021-05-25 Impact factor: 24.094
Authors: Thomas A Kite; Amerjeet S Banning; Andrew Ladwiniec; Chris P Gale; John P Greenwood; Miles Dalby; Rachel Hobson; Shaun Barber; Emma Parker; Colin Berry; Marcus D Flather; Nick Curzen; Adrian P Banning; Gerry P McCann; Anthony H Gershlick Journal: BMJ Open Date: 2022-05-03 Impact factor: 3.006
Authors: Cole R Clifford; Michel Le May; Alyssa Chow; Rene Boudreau; Angel Y N Fu; Quinton Barry; Aun Yeong Chong; Derek Y F So Journal: CJC Open Date: 2020-12-15